Key result
Anthracycline-free targeted therapies reduce cardiotoxicity compared to anthracycline regimens in HER2-positive breast cancer, though cardiac monitoring remains essential.
Why the study?
Anthracyclines cause cardiotoxicity in breast cancer treatment, prompting the use of anthracycline-free therapies to reduce cardiovascular toxicity while maintaining therapeutic efficacy in HER2-positive breast cancer.
Does anthracycline-free targeted therapy reduce cardiotoxicity compared to anthracycline-based therapy in patients with HER2-positive breast cancer?
Does anthracycline-free targeted therapy reduce cardiotoxicity compared to anthracycline-based therapy in patients with HER2-positive breast cancer?
Anthracycline-free targeted therapies reduce cardiotoxicity in HER2-positive breast cancer but still require routine cardiovascular monitoring using echocardiography, ECG, and biomarkers.
Answers are grounded in this paper and cite their sources.
Supports consideration of anthracycline-free regimens in HER2+ breast cancer; leaves open prospective RCTs for long-term cardiac outcomes.
Anthracycline drugs are considered to be pivotal drugs in numerous chemotherapy regimens for breast cancer. However, the cardiotoxicity associated with the treatment is an important issue to be addressed. With the emergence of increasingly diverse antitumor drugs, anthracycline-free therapies are able to reduce the cardiotoxicity caused by anthracycline drugs while ensuring that a therapeutic effect is achieved. In the present review, anthracycline-free oncological therapy regimens for the treatment of patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer and the associated cardiovascular toxicity are discussed, as well as some monitoring strategies. It is recommended that patients with HER2-positive breast cancer patients should receive adjuvant chemotherapy with single or dual-targeted therapy, with or without endocrine therapy according to the hormone receptor status determined by immunohistochemical examination. The main side effects of targeted therapy include cardiac dysfunction, hypertension and arrhythmia. According to individual risk stratification, it is recommended that patients should be periodically monitored using echocardiography, electrocardiography and serum markers, to enable the timely detection of the cardiovascular adverse reactions associated with tumor treatment, thereby preventing the morbidity and mortality caused by the cardiotoxicity of these drugs.
No takes yet. Share an insight, caveat, or question.
Guan et al. (2020) conducted a review in HER2-positive breast cancer. Anthracycline-free targeted therapies vs. Anthracycline-based therapies was evaluated. Anthracycline-free targeted therapies reduce cardiotoxicity compared to anthracycline regimens in HER2-positive breast cancer, though cardiac monitoring remains essential.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: